OssDsign is a Swedish MedTech company founded in 2011 and headquartered in Uppsala, developing next generation orthobiologics based on advanced materials science. The company focuses on improving outcomes in spinal fusion, where current bone graft solutions are often inconsistent and a significant share of procedures fail to achieve proper healing.
The company’s lead product, OssDsign Catalyst, is a nanosynthetic bone graft designed to mimic natural bone mineral and drive fast, reliable bone formation. Its patented nanostructure enables consistent healing even in challenging patients, supporting a shift toward more predictable spinal fusion outcomes. Catalyst is FDA-cleared, including for use in interbody cages, and has been used in thousands of spine procedures in the US with strong clinical results, including high fusion rates.
